Related Experiment Video
Updated: Jan 31, 2026

Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy
Published on: August 14, 2012
A Neuroendocrine Tumor of Unknown Primary Origin that Responded to Treatment Based on Tumor Grade Progression
Yukako Hamano1, Toshikazu Moriwaki1, Keii To1
1Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Japan.
Abstract:
The standard chemotherapies for neuroendocrine tumors (NETs) are somatostatin analog (SSA) and targeted-agents for NET G1/G2 and platinum-based chemotherapy for neuroendocrine carcinoma (NEC), classified according to the WHO criteria of 2010. We report a case of NET, in which tumors were successfully treated with platinum-containing chemotherapy after remarkable progression with SSA. A 46-year-old man with multiple lymph nodes and liver metastases of unknown primary origin was diagnosed with NET G2 based on the examination of a biopsy specimen. His tumors were stable with SSA for a year, but rapidly became enlarged. A second biopsy revealed NEC. He received cisplatin plus etoposide, and his tumors showed a marked reduction in size.
Insights
Neuroendocrine tumors (NETs) initially treated with somatostatin analogs (SSAs) can progress to neuroendocrine carcinoma (NEC). Platinum-based chemotherapy effectively treated a patient's NEC after SSA failure, demonstrating a successful treatment shift.
Area of Science:
- Oncology
- Medical Research
Background:
- Standard treatments for neuroendocrine tumors (NETs) include somatostatin analogs (SSAs) for G1/G2 NETs and platinum-based chemotherapy for neuroendocrine carcinoma (NEC).
- Accurate classification of NETs is crucial for determining appropriate therapeutic strategies.
Observation:
- A 46-year-old male patient with metastatic NET G2 showed initial stability with SSA treatment for one year.
- Tumor progression was observed, and a subsequent biopsy revealed a transformation to neuroendocrine carcinoma (NEC).
Findings:
- The patient received platinum-based chemotherapy (cisplatin plus etoposide) following the NEC diagnosis.
- Significant tumor size reduction was achieved with the platinum-containing chemotherapy regimen.
Implications:
- This case highlights the potential for NETs to dedifferentiate into NEC and the efficacy of platinum-based chemotherapy in such advanced cases.
- It suggests a potential treatment pathway for patients with advanced NETs that progress despite SSA therapy.
More Related Videos
Related Concept Videos
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Immunotherapy
The Tumor Microenvironment
Graded Potential
Graded potentials fall into two categories: depolarizing and hyperpolarizing. Depolarizing graded potentials typically occur when sodium (Na+) or...
Testing a Claim about Mean: Unknown Population SD
Estimating a population mean requires the samples to be approximately normally distributed. The data should be collected from the randomly selected samples having no sampling bias. There is no specific requirement for sample size. But if the sample size is less than 30, and we don't know the population standard deviation, a different approach is used;...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

